Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET

Genprex to Present at NobleCon17 on January 19

AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Cardiff Oncology

Novavax

Trillium Therapeutics

Vaxart

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.

5 Biotech Stocks That Generated 1,000%+ Returns In 2020

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces $12 million registered direct closing.

Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market u

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to data from the World Health Organization, cancer is currently the second leading cause of death worldwide, and unfortunately, this number is only expected to rise.

Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes clinical-grade manufacturing of lead drug candidate, REQORSA

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes major manufacturing milestone with completion of technology transfer

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for Acclaim-1 clinical trial

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's COO will present on December 1 at the Diamond Equity Research Emerging Growth Invitational

Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Thomas Gallagher will participate as a panelist at the NYC-based Life Sciences Summit

Genprex to Participate in Panel at Life Sciences Summit on November 17

AUSTIN, Texas--(BUSINESS WIRE)--George Gittes, MD Joins Genprex's Scientific Advisory Board

Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces new clinical trial branding for upcoming trials in non-small cell lung cancer

Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex receives conditional FDA acceptance of proprietary name Reqorsa(TM) for lead drug candidate

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints Eric Chapdelaine to VP of Manufacturing

Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Zooming with LD Micro virtual event

Genprex to Present at Zooming with LD Micro on October 14, 2020

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Cell and Gene Meeting on the Mesa

Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints new Vice President of Regulatory Affairs

Genprex Appoints William E. Gannon, Jr.

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Chairman and CEO will present on September 1, 2020 at the LD 500 Virtual Conference

Genprex to Present at The LD 500 Virtual Conference

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will Present at the Proactive Investor Forum on August 4 at 1:40 p.m. ET

Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appears live on the Big Biz Show for a second time

Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's collaborators at the University of Pittsburgh receive $2.5 million grant from the NIH to fund diabetes gene therapy study.

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday.

Why Are Shares Of Gene Therapy Company Genprex Are Surging Higher

Shares of Genprex Inc. GNPX, +56.61% climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation.

News for Genprex Stock (GNPX)